Research programme: inflammatory bowel disease - Sanofi
Alternative Names: GENZ 38167; Inflammatory bowel disease research programme - SanofiLatest Information Update: 01 Apr 2022
Price :
$50 *
At a glance
- Originator Genzyme Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 04 May 2006 No development reported - Preclinical for Inflammatory bowel disease in USA (unspecified route)
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
- 18 Jun 2003 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)